NEW HAVEN, Conn., Oct 14, 2008 (BUSINESS WIRE) -- Ikonisys, a leading provider of next-generation, cell-based diagnostic solutions, today announced positive results from a clinical study conducted by a research group at the Weatherall Institute of Molecular Medicine at Oxford University, a laboratory supported by Cancer Research U.K. (CRUK), the country's leading cancer charity. The study validates the company's CellOptics(R) platform and proprietary digital microscope, the Ikoniscope(R), as a viable method for quickly and easily detecting and detailing circulating tumor cells (CTC) in the blood. The findings, published in the British Journal of Cancer (September 2008), represent a significant milestone for screening and disease monitoring for a variety of cancers, including prostate, colorectal and ovarian.
